Clinical Trial Update: Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer [Phase 3]

View source ↗

Summary

Phase III open-label study of MEDI4736 (durvalumab) with/without tremelimumab versus standard of care in recurrent/metastatic head and neck squamous cell carcin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• MEDI4736 (Durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: AstraZeneca | Conditions: Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Status: COMPLETED | Results posted: 2021-10-13